Boston Scientific reported net sales of $2.932 billion for Q3 2021, representing a 10.3% increase on a reported basis and a 10.6% increase on an organic basis. GAAP net income available to common stockholders was $0.28 per share, compared to a net loss of $(0.12) per share in the prior year, with adjusted EPS reaching $0.41. The company's growth strategy and recent acquisitions have positioned it well for long-term success.
Net sales reached $2.932 billion, up 10.3% reported and 10.6% organic.
GAAP EPS was $0.28, compared to $(0.12) in the prior year.
Adjusted EPS was $0.41, compared to $0.37 a year ago.
Completed acquisitions of Lumenis LTD.'s global surgical business and Farapulse, Inc.
The company estimates net sales growth for the full year 2021 to be in a range of approximately 19 to 20 percent on a reported basis, and approximately 18 to 19 percent on an organic basis. The company estimates net sales growth for the fourth quarter of 2021 to be in a range of approximately 13 to 17 percent on a reported basis, and approximately 12 to 16 percent on an organic basis.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance